Cholera Vaccines Market Growth, Size, Trends Analysis - By Type, By Product, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Cholera Vaccines Market Introduction and Overview

According to SPER market research, 'Global Cholera Vaccines Market Size- By Type, By Product, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Cholera Vaccines Market is predicted to reach 222.23 million by 2034 with a CAGR of 8.63%.

Cholera vaccines are biological preparations that give active immunity to cholera, an acute diarrheal disease caused by the bacterium Vibrio cholerae. These vaccinations are intended to boost the immune system in order to prevent the disease from developing after exposure to the pathogen. The market is expected to grow due to more awareness of cholera outbreaks in areas where it is common. There are various vaccination options, including oral and injectable forms. International health organizations and government programs support vaccination campaigns to reduce outbreaks.

Restraints: Vaccine development takes a long time, and tight regulatory clearances are expected to limit market growth throughout the projection period. Vaccine manufacture is time-consuming and costly. Furthermore, cholera vaccines may have adverse impacts on human health. Regulatory clearance for individual vaccines take a lengthy time. These considerations are predicted to limit the market for cholera vaccines in the coming years.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Type, By Product, By Distribution Channel.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Valneva SE, Sanofi S.A, Astellas Pharma, Inc, Emergent BioSolutions Inc, PavVax Inc, EuBiologics Co., Ltd, Shantha Biotechnics Limited, Hilleman Laboratories, Astellas Pharma Inc, Incepta Vaccine Ltd, Vabiotech. and others.

Cholera Vaccines Market Segmentation:

By Type: Based on the Type, Global Cholera Vaccines Market is segmented as; Whole Cell v. Cholerae O1 with Recombinant B- subunit, Killed Oral O1 and O139.

By Product: Based on the Product, Global Cholera Vaccines Market is segmented as; Vaxchora, Dukoral, Shanchol, Other products.

By Distribution Channel: Based on the Distribution Channel, Global Cholera Vaccines Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Other.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA2550

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Cholera Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cholera Vaccines Market

7. Global Cholera Vaccines Market, By Type (USD Million) 2021-2034

7.1. Whole Cell v. Cholerae O1 with Recombinant B- subunit
7.2. Killed Oral O1 and O139

8. Global Cholera Vaccines Market, By Product (USD Million) 2021-2034

8.1. Vaxchora
8.2. Dukoral
8.3. Shanchol
8.4. Other products

9. Global Cholera Vaccines Market, By Distribution Channel (USD Million) 2021-2034

9.1. Hospital Pharmacy
9.2. Retail Pharmacy
9.3. Other

10. Global Cholera Vaccines Market, (USD Million) 2021-2034

10.1. Global Cholera Vaccines Market Size and Market Share

11. Global Cholera Vaccines Market, By Region, (USD Million) 2021-2034

11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America

12. Company Profile

12.1. Valneva SE
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Sanofi S.A
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Emergent BioSolutions Inc
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. PaxVax Inc
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. EuBiologics Co., Ltd
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Shantha Biotechnics Limited
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Hilleman Laboratories
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Astellas Pharma Inc
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Incepta Vaccine Ltd
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Vabiotech
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others